



Seroprevalence of *Helicobacter pylori* Infection among Adults in Port Harcourt Metropolis, Nigeria

Chidi L.C. Ndukwu ^{a*}, Owhorchukwu Amadi-Wali ^b
and Roseanne Adah Ikpeama ^c

^a Faculty of Medical Laboratory Science, Federal University, Otuoke, Bayelsa State, Nigeria.

^b Faculty of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

^c Department of Medical Laboratory Science, PAMO University of Medical Sciences, Port Harcourt, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/124552>

Original Research Article

Received: 03/08/2024

Accepted: 05/10/2024

Published: 09/10/2024

ABSTRACT

Introduction: *Helicobacter pylori* is a highly evolved and adapted pathogen, notorious for having infected half of all the people in the world. It is linked as a causative agent for numerous benign and malignant diseases of the digestive tract, such as peptic ulcer disease (PUD) and gastric cancer. This study was conceived to determine the seroprevalence of *Helicobacter pylori* in urban communities of Port Harcourt, Nigeria.

Materials and Methods: This retrospective cross-sectional study involved a review of laboratory records of persons resident in the study area between January 2022 and December 2023. The results of the laboratory tests of *Helicobacter Pylori* tests and relevant socio-demographic

*Corresponding author: E-mail: chidisteve.cn@gmail.com;

data about the ages, genders and areas of residence were extracted, coded and anonymously analyzed.

Results: The overall seroprevalence of *H. pylori* infection in the study area was found to be 34.6%. The prevalences for specific urban communities were Mile I (23.9%), Mile II (43.3%), Mile III (37%) and adjoining urban communities (32.1%). The seroprevalence for males was 35.9% and 33.6% for females. Among the age groups, the highest seroprevalence was observed with the 30-39 age group (38.9%), 40-49 age group (37.8%), 60-69 age group (35.3%), 18-29 age group (32.8%) and 50-59 age group (25.6%).

Conclusion: The study has contributed to the body of knowledge on the seroprevalence *H Pylori* infections the urban communities. The findings will go a long way in assisting public health authorities in the policy design and implementation for the prevention and control programs for malignant and benign digestive diseases associated with the bacteria.

Keywords: *Helicobacter pylori*; Diobu port harcourt; seroprevalence; peptic ulcer disease; gastric cancer; digestive diseases.

1. INTRODUCTION

The discovery of *Helicobacter pylori* (*H. pylori*) in 1982 by Barry J. Marshall and Robin Warren marked a watershed in the scientific understanding and management of peptic ulcer disease (PUD) and other conditions associated with the bacteria; and earned the two scientists a Nobel prize in Physiology or Medicine in 2005 [1]. Before their landmark breakthrough, PUD was seen as a non-infectious disease caused by some types of diets, stress and related factors. *Helicobacter pylori*, is a ubiquitous, highly motile, microaerophilic, short helical, gram-negative bacterium, measuring 0.5–1 µm width, 2–4 µm in length; which may also appear as a rod, while coccoid shapes may be noticed after long-term in vitro culture or exposure to antimicrobial agents [1,2].

H. pylori is notorious for infecting nearly half of the world population, with a global prevalence of 43.1% in 2022, down from an earlier 58.2% in 1990.³ The African continent is known to bear the heaviest burden of *H. pylori* with a pooled prevalence of 70.1% [3]. The prevalence varies widely depending on sociodemographic factors such as age, health conditions, geography, race, socioeconomic status, and hygienic conditions [3]. *H. pylori* infection is highly prevalent in children and adolescents globally [4]. Other predisposing factors include older age, poor hygiene conditions, crowded households, having infected close relations, drinking non-treated water, and low socioeconomic status [5]. Recent studies put the estimated number of persons infected globally with *H. pylori* at 4.4 billion; Nigeria, Portugal, Estonia, Kazakhstan, and Pakistan are the countries with highest population of infected persons [2].

H. pylori infection is a highly evolved pathogen with the ability to colonize the gastric mucosa and tenaciously infect the stomach walls for long period, possibly the entire lifetime. The its efficient adaptability to the acidic and perilous gastric environment may have accounted a lot of immune responses leading to disparate pathological outcomes associated with the bacteria [1]. It has been linked with numerous benign and malignant diseases of the digestive tract, such as peptic ulcer disease (PUD) and gastric cancer [6].

It is the major causative agent for peptic ulcer disease accounting for nearly 80% of stomach ulcer and 90% of duodenal ulcer; it is also associated with chronic active gastroenteritis, stomach cancers and mucosa-associated lymphoid tissue lymphoma [7]. It is in the same class 1 biologic carcinogens category with viral infections such as hepatitis B and C viruses, human immunodeficiency virus, and human papillomavirus as classified by the International Agency for Research on Cancer, World Health Organization (IARC/WHO) [5]. Complications of *H. pylori* infection extend beyond the digestive system and includes iron deficiency anaemia, vitamin B12 deficiency, cardiovascular diseases immune thrombocytopenic purpura, diabetes mellitus, and neurological disorders [4].

The diagnosis and management of *H. pylori* infections are varied and dependent on several factors [8] the diagnostic tests fall into two categories, the invasive and non-invasive tests. The invasive procedure include endoscopy, histology, rapid urease test [RUT], bacterial culture from biopsy; while non-invasive tests include serological, urea breath test (UBT) and the stool antigen test (SAT). There are also

molecular techniques like PCR, real-time PCR, fluorescence in situ hybridization, and peptide mass fingerprinting [7,9]. Each of the techniques have merits and demerits and choice of techniques depends on careful considerations of these factors.

To the extent of our knowledge, there has been no study to ascertain the prevalence *H. pylori* of at the level of urban communities in Port Harcourt metropolis. This study was therefore conceived to fill this gap by determining the seroprevalence of *Helicobacter pylori* infection in a high-density community within an urban city in the Niger delta region of Nigeria.

2. MATERIALS AND METHODS

2.1 Study Area

The study area, Diobu is a high-density collection of urban communities situated in the heart of Port Harcourt metropolis in the Niger Delta of Nigeria. The notable urban communities are Mile I, Mile II and Mile III urban communities. The coordinates of Diobu are: 4°47'24"N, 6°59'36"E (Latitude:4.772152; Longitude:6.994514). It is bordered on the north by New GRA, on the northeast by D-line, on the northwest Rivers State University, on the east by Old GRA, on the southeast by Kidney Island, and on the southwest by Eagle Island.

Many households live in overcrowded rooms, with some rooms harboring more than four occupants. The residents depend on untreated borehole sources for water supply. There are toilet facilities in almost every home but there are cases of open defecation due to presence of vagrants and homeless persons found in every urban city in Nigeria. There are also large numbers of families occupying shanties across the Diobu watersides who defecate into the waters and on bare grounds.

2.2 Design of the Study

This is a retrospective cross-sectional study conducted from 3rd January 2022 to 3rd December 2023 involving 211 adult males and female residents of Diobu and closely adjoining urban communities of Port Harcourt metropolis; attending public and private healthcare facilities within the area. The inclusion criteria include persons who are 18 years and living withing mile I, mile II and mile III and closely adjoining neighborhoods such as Agip, Eagle Island, D-line

etc., who within the study period, conducted serological laboratory investigations for IgG anti-*H. pylori* antibodies (SD Biotine) at Diagnostix and Scientifique Laboratories, Port Harcourt. Persons below the age of 18 years, those living far from Diobu or did not perform the two tests were excluded.

2.3 Data Collection

Patients' data were obtained by going through their medical laboratory records. The outcomes of the laboratory tests of *Helicobacter Pylori* tests and relevant socio-demographic data about the ages, genders and areas of residence were extracted, coded and anonymously analyzed.

2.4 Statistical Analysis

Data were analyzed with IBM SPSS Statistics version 25. Descriptive statistics were employed in presenting the data were in counts and percentages. Pearson chi-square test and Fishers exact test were employed to ascertain associations between the categorical variables.

3. RESULTS

The study involved 211 blood specimens obtained from persons attending public and private healthcare facilities in Diobu, Port Harcourt, Rivers State Nigeria. The ages ranged from 18 to 69 years, the mean age was 38.26 (standard deviation 13.25), the median was 37, while the age with the highest frequency was 38 years. The number of males were 103 (48.8%), while the females were 108 (51.2%).

3.1 Seroprevalence of *Helicobacter pylori* in Diobu and Adjoining Urban Communities

The overall seroprevalence of *H. pylori* infection in Diobu and adjoining communities was found to be 34.6% in the sample areas. The seroprevalence for males was 35.9% and 33.6% for females. Among the age groups, the highest seroprevalence was observed with the 30-39 age group (38.9%). 40-49 age group 37.8%, 60-69 age group (35.3%), 18-29 age group (32.8%) and 50-59 age group 25.6% (Table 1.).

3.2 Seroprevalence of *Helicobacter pylori* in Mile I Diobu, Port Harcourt

The seroprevalence of *Helicobacter pylori* in Mile I Diobu was 23.9%; the males had a prevalence

of 21.1% and women had 29.2%. The 18-29 age group had a zero prevalence while the 30-39 had 28.6%; 40-49 (30); 5-59 (33.3%) and 60-69 (50) (Table 2).

Table 1. Seroprevalence of *Helicobacter pylori* in Diobu and Adjoining Communities

Characteristics	No. Tested	No. Positive
Age	n (%)	n (%)
18-29	64 (30.3)	21 (32.8)
30-39	54 (25.6)	21 (38.9)
40-49	45 (21.3)	17 (37.8)
50-59	31 (14.7)	8 (25.6)
60-69	17 (8.1)	6 (35.3)
Total	211 (100)	73 (34.6)
Genders		
Males	103 (48.8)	37 (35.9)
Females	108 (51.2)	36 (33.3)
Total	211 (100)	73 (34.6)
Residence		
Mile I	41(100)	11 (23.9)
Mile II	55 (100)	24 (43.3)
Mile III	54 (100)	20 (37)
Adjoining Communities	56 (100)	18 (32.1)
Total	211 (100)	73 (34.6)

Table 2. Seroprevalence of *Helicobacter pylori* in Mile I, Diobu, Port Harcourt

Characteristics	No. Tested	No. Positive
Age		
18-29	7(17.1)	0(0)
30-39	14(34.2)	4(28.6)
40-49	10(24.4)	3(30)
50-59	6(14.6)	2(33.3)
60-69	4(9.8)	2(50)
Total	41(100)	11(23.9)
Genders		
Males	19(41.3)	4(21.1)
Females	24(52.2)	7(29.2)
Total	41(100)	11(23.9)

Table 3. Seroprevalence of *Helicobacter pylori* in Mile II, Diobu, port harcourt

Characteristics	No. Tested	No. Positive
Age		
18-29	20 (37)	7 (35)
30-39	14 (25.9)	6 (42.9)
40-49	7 (13)	2 (28.6)
50-59	8 (14.8)	2 (25)
60-69	5 (9.3)	3 (75)
Total	54 (100)	20 (37)
Genders		
Males	26 (48.2)	10 (38.5)
Females	28 (55.6)	10 (35.7)
Total	54 (100)	20 (37)

Table 4. Seroprevalence of *Helicobacter pylori* in Mile III, Diobu, Port Harcourt

Characteristics	No. Tested	No. Positive
Age		
18-29	18 (32.7)	9 (37.5)
30-39	12 (21.8)	6 (25)
40-49	10 (18.2)	5 (20.8)
50-59	11 (20)	3 (12.5)
60-69	4 (7.3)	1 (4.2)
Total	55 (100)	24 (43.3)
Genders		
Males	30 (54.6)	14 (46.7)
Females	25 (45.5)	10 (40)
Total	55 (100)	24 (43.3)

Table 5. Seroprevalence of *Helicobacter pylori* in Adjoining Communities to Diobu, Port Harcourt

Characteristics	No. Tested	No. Positive
Age		
18-29	16 (28.6)	5 (31.3)
30-39	14 (25)	5 (35.7)
40-49	18 (32.1)	7 (38.9)
50-59	6 (10.7)	1 (16.7)
60-69	2 (3.6)	0 (0)
Total	56 (100)	18 (32.1)
Genders		
Males	25(44.6)	9 (36)
Females	31(55.4)	9 (29)
Total	56 (100)	18 (32.1)

3.3 Seroprevalence of *Helicobacter pylori* in Mile II, Diobu, Port Harcourt

The group seroprevalence for Mile II Diobu was observed to be 43.3%; the seroprevalence for males was 46.7%, females 40%; the 60-69 age group had zero prevalence, while the prevalence for 18-29 was 35.7%, 30-39 (28.6%), 40-49 (14.3%) and 50-59 (21.1).

3.4 Seroprevalence of *Helicobacter pylori* in Mile III, Diobu, Port Harcourt

The group seroprevalence for Mile III Diobu was observed to be 37%; the seroprevalence for males was 38.5%, females 35.7%; the 18-39 age group had a prevalence of 35%, the prevalence for 30-39 (57.1%), 40-49 (13%) and 50-59 (14.3%) and 60-69 (9.3%).

3.5 Seroprevalence of *Helicobacter pylori* in Adjoining Communities to Diobu, Port Harcourt

The group seroprevalence for the adjoining communities to Diobu was observed to be

32.1%; the seroprevalence for males was 36%, females 29%; the 18-39 age group had a prevalence of 31.3%, the 30-39 (35.7%), 40-49 (38.9%) and 50-59 (16.7%) and 60-69 (0).

4. DISCUSSION

This Study has been able to ascertain the seroprevalence of *Helicobacter pylori* in Diobu and adjoining communities within Port Harcourt metropolis. The seroprevalence of 34.6% observed in this study was within the range of 28–51.4% reported as the prevalence in southern Nigeria [10]. It aligned closely with the 38.5% observed in Port Harcourt [11], a bit lower than 42.8% reported in Ethiopia [12] but much lower than the seroprevalence of 63% reported among patients attending a tertiary hospital in Port Harcourt [13] This may be indicative of improved standards of hygiene in the study area and correlates with observations of declining trends in the prevalence of the bacterial infection globally [3,4].

The seroprevalence was higher than the prevalence of 26.6% reported in Taiwan, which

was also a decline from previous reports [4]. It was however lower than the 42.8% reported in adult patients attending public health facilities of Mizan Aman Town, Southwest Ethiopia; [11] and the 43.9% reported as the global pooled prevalence. A study in Ethiopia also reported a similar prevalence (34%) in dyspepsia patients attending a Comprehensive Specialized Hospital [14]. It appears that in Nigeria and across parts of Africa, efforts aimed at controlling *H pylori* infections are yielding positive results as seen with lower prevalences that what was obtainable in the past.

Age was observed to be a factor in the infection as over 80% of the infected persons were in the 18-49 age group which are the most active age group. This corroborates the findings of a study in United Arab Emirates that age is a factor in *H. pylori* infection [15]. While gender was observed as not being a factor as has been reported in a number of studies; [16] some studies have reported that the female gender as being more likely to be infected than the males [5,17]. More studies are required to unravel the reasons behind the discrepancies in the outcomes of the studies.

The seroprevalence of *Helicobacter pylori* in Mile I Diobu was the least of all the four communities in the study. This may be attributable to more improved hygienic standards, it may also be due to the low number of participants compared with the other communities. Poor hygienic standards have been a major factor associated with *H. pylori* infection [18].

The highest prevalence of the four study areas was 43.3% recorded in the mile II area of Diobu, which a very close neighbourhood to mile I. A better understanding of the wide disparity may require further studies but a lot more efforts need to be channeled towards combating the situation. The factors may be attributable to the poor hygienic conditions and overcrowding associated with the slums or watersides of the area [19].

The mile III and adjoining urban communities with seroprevalences of 37% and 32.1% respectively are more closely aligned to the overall prevalence. While the outcomes reported here are lower than previous reports and what is still found in some areas of Africa, efforts must be intensified to eradicate the scourge of *H pylori*.

The limitations of the study are largely as encountered in other retrospective studies, due

to the fact of the samples having been analyzed and results obtained prior to the commencement of the study. Also, sociodemographic data used in the study are only those contained in the laboratory records, and there is no personal interaction with the participants. Some information that may enrich the study are therefore not captured. Prospective studies may be designed as follow-up to improve on the overcome the study [20].

5. CONCLUSION

This study has been able to ascertain the seroprevalence of *H pylori* in some urban communities within Port Harcourt metropolis. This, to our knowledge is the first of such a study and has contributed in the body of knowledge required to for informed planning and decision making on the strategies for the prevention and control of *H pylori* in the area. The prevalence of 34.6% in this study is a call for action on public health authorities to intensify efforts at creating public awareness and other interventions aimed to tame the scourge.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The study was reviewed and approved by ethical review committee of the Faculty of Medical Laboratory Science, Federal University Otuoke, Nigeria. Relevant approvals were sought and obtained from the management of Diagnostix and Scientific Laboratories.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ali A, AlHussaini KI. *Helicobacter pylori*: A contemporary perspective on

- pathogenesis, diagnosis and treatment strategies. *Microorganisms*. 2024;12(1):222.
DOI:10.3390/microorganisms12010222.
PMID: 38276207; PMCID: PMC10818838.
2. Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of *Helicobacter pylori* Infection: Clinical features, treatment, and nutritional aspects. *Diseases*. 2021;9(4):66.
DOI: 10.3390/diseases9040066.
PMID: 34698140; PMCID: PMC8544542.
 3. Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, Wu CY, Lin JT, O'Morain C, Megraud F, Lee WC, El-Omar EM, Wu MS, Liou JM. Global prevalence of helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. *Gastroenterology*. 2024;166(4):605-619.
DOI: 10.1053/j.gastro.2023.12.022.
Epub 2024 Jan 2. PMID: 38176660.
 4. Chen MJ, Bair MJ, Chen PY, Lee JY, Yang TH, Fang YJ, Chen CC, Chang AT, Hsiao WD, Yu JJ, Kuo CC, Chiu MC, Lin KP, Tsai MH, Hsu YC, Chou CK, Chen CY, Lin JT, Lee YC, Wu MS, Liou JM; for the Taiwan gastrointestinal disease and helicobacter consortium. declining trends of prevalence of helicobacter pylori infection and incidence of gastric cancer in taiwan: an updated cross-sectional survey and meta-analysis. *Helicobacter*. 2022;27(5):e12914.
DOI: 10.1111/hel.12914.
Epub 2022 Jul 18. PMID: 35848363.
 5. Alshareef SA, Hassan AA, Abdelrahman DN, AlEed A, Al-Nafeesah A, Adam I. The prevalence and associated factors of *Helicobacter pylori* infection among asymptomatic adolescent schoolchildren in Sudan: a cross-sectional study. *BMC Pediatr*. 2023;23(1):582.
DOI: 10.1186/s12887-023-04411-5.
PMID: 37985974;
PMCID: PMC10662923.
 6. Borka Balas R, Meliț LE, Mărginean CO. Worldwide Prevalence and Risk Factors of *Helicobacter pylori* Infection in Children. *Children (Basel)*. 2022;9(9):1359.
DOI: 10.3390/children9091359.
PMID: 36138669; PMCID: PMC9498111.
 7. Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, Almuzaini AM, Rawway M, Alfadhel A, Draz A, Abu-Okail A. *Helicobacter pylori* Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. *Antibiotics (Basel)*. 2023;12(2):191.
doi: 10.3390/antibiotics12020191.
PMID: 36830102; PMCID: PMC9952126.
 8. Protopapas AA, Papagiouvanni I, Protopapas AN, Goulis I. *Helicobacter pylori* infection diagnosis and management: Current practices of Greek gastroenterologists. *Ann Gastroenterol*. 2024;37(1):15-21.
DOI: 10.20524/aog.2024.0844.
Epub 2023 Dec 20. PMID: 38223245; PMCID: PMC10785018.
 9. Duquesne A, Falcón R, Galindo B, Feliciano O, Gutiérrez O, Baldoquín W, Fonseca MC, Llanes R, Sarmiento L. Diagnostic Testing Accuracy for *Helicobacter pylori* Infection among Adult patients with dyspepsia in Cuba's Primary Care Setting. *Microorganisms*. 2023;11(4):997.
DOI:10.3390/microorganisms11040997.
PMID: 37110419; PMCID: PMC10146794.
 10. Emmanuel BN, Peter DA, Peter MO. *Helicobacter pylori* infection in Africa: comprehensive insight into its pathogenesis, management, and future perspectives. *J.Umm Al-Qura Univ. Appl. Sci*; 2024).
Available:https://doi.org/10.1007/s43994-024-00166-6
 11. Ray-Offor E, Obiorah CC. *Helicobacter pylori* and precancerous lesions of the stomach in a Nigerian Metropolis: A Cohort Study. *Niger J Clin Pract*. 2018;21(3):375-379.
DOI: 10.4103/njcp.njcp_302_17.
PMID: 29519989.
 12. Belay AS, Abateneh DD, Yehualashet SS. Seroprevalence of *Helicobacter pylori* Infection and Associated Factors Among Adult Dyspeptic Patients in Public Health Facilities, Mizan Aman Town, Southwest, Ethiopia: Institutional-Based Cross-Sectional Study. *Int J Gen Med*. 2020;13:577-585.
DOI: 10.2147/IJGM.S273523.
PMID: 32982374; PMCID: PMC7490056.
 13. Lawson SD. NMA/AGSM/2022/BCS/005 - Serological probing of helicobacter pylori infections in patients seeking care at the Rivers State University Teaching Hospital. *Niger Med J*. 2023;64(1):124.
PMCID: PMC11180277.
 14. Jemere T, Tilahun M, Walle G, Yideg G, Agegnehu A, Tilahun A, Abebe E, Moges N. *Helicobacter pylori* infection and its

- associated factors among dyspepsia patients attending Debre Tabor Comprehensive Specialized Hospital, 2020. *PLoS One*. 2023;18(3):e0279396. DOI:10.1371/journal.pone.0279396. PMID: 36893138; PMCID: PMC9997881.
15. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Buruoca C. Prevalence of *Helicobacter pylori* and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. *Pathogens*. 2019;8(2):44. DOI: 10.3390/pathogens8020044. PMID: 30939800; PMCID: PMC6632043.
16. Aitila P, Mutyaba M, Okeny S, Ndawula Kasule M, Kasule R, Sseddyabane F, Okongo B, Onyuthi Apecu R, Muwanguzi E, Oyet C. Prevalence and Risk Factors of *Helicobacter pylori* Infection among Children Aged 1 to 15 Years at Holy Innocents Children's Hospital, Mbarara, South Western Uganda. *J Trop Med*. 2019;2019:9303072. doi: 10.1155/2019/9303072. PMID: 30984271; PMCID: PMC6431523.
17. Mehata S, Parajuli KR, Pant ND, Rayamajhee B, Yadav UN, Mehta RK, et al. Prevalence and correlates of *helicobacter pylori* Infection among under-five children, adolescent and non-pregnant women in Nepal: further analysis of Nepal national micronutrient status survey 2016. *PLoS Negl Trop Dis*. 2021; 15:e0009510. DOI: 10.1371/journal.pntd.0009510. [PMC free article]
18. Thorat JV, Tambolkar S, Chitale MM, Biradar V, Jadhav RS. Association of *Helicobacter pylori* in Children With Self-Hand Hygiene, Maternal Hand Hygiene, Cooking, and Feeding Practices. *Cureus*. 2024;16(3):e56554. DOI: 10.7759/cureus.56554. PMID: 38646320; PMCID: PMC11027946..
19. Smith S, Fowora M, Pellicano R. Infections with *Helicobacter pylori* and challenges encountered in Africa. *World J Gastroenterol*. 2019;25(25):3183-3195. DOI: 10.3748/wjg.v25.i25.3183. PMID: 31333310; PMCID: PMC6626727..
20. Ndukwu, CLC. Microbial communities and antimicrobial resistance patterns in aerobic bacteria associated with the vaginal microbiota: A Retrospective Study in Port Harcourt, Nigeria. *Asian Journal of Research in Infectious Diseases*. 2024;15(1):39–48. Available: <https://doi.org/10.9734/ajrid/2024/v15i1324>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/124552>